ticlopidine has been researched along with Coronary Occlusion in 14 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Coronary Occlusion: Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.
Excerpt | Relevance | Reference |
---|---|---|
" No data exist about the impact of HRPR after 600 mg clopidogrel loading on long-term clinical outcome in patients with diabetes mellitus and treated with percutaneous coronary angioplasty (PCI) for chronic total occlusion (CTO)." | 3.81 | Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. ( Abbate, R; Antoniucci, D; Cantini, G; Carrabba, N; Cerisano, G; Comito, V; Gensini, GF; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Parodi, G; Valenti, R; Vergara, R, 2015) |
"CABG had similar rates of cardiac death compared with PCI group (HR=0." | 1.42 | Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication. ( Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, WJ; Kim, BS; Kim, WS; Lee, SH; Lee, YT; Song, YB; Yang, JH, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.14) | 29.6817 |
2010's | 12 (85.71) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
Authors | Studies |
---|---|
Parker, WA | 1 |
Bhatt, DL | 1 |
Prats, J | 1 |
Day, JRS | 1 |
Steg, PG | 1 |
Stone, GW | 1 |
Hamm, CW | 1 |
Mahaffey, KW | 1 |
Price, MJ | 1 |
Gibson, CM | 1 |
White, HD | 1 |
Storey, RF | 1 |
Martin, J | 1 |
Williams, AK | 1 |
Klein, MD | 1 |
Sriramoju, VB | 1 |
Madan, S | 1 |
Rossi, JS | 1 |
Clarke, M | 1 |
Cicci, JD | 1 |
Cavallari, LH | 1 |
Weck, KE | 1 |
Stouffer, GA | 1 |
Lee, CR | 1 |
Sorich, MJ | 1 |
Rowland, A | 1 |
McKinnon, RA | 1 |
Wiese, MD | 1 |
Kim, BS | 1 |
Yang, JH | 1 |
Jang, WJ | 1 |
Song, YB | 1 |
Hahn, JY | 1 |
Choi, JH | 1 |
Kim, WS | 1 |
Lee, YT | 1 |
Gwon, HC | 1 |
Lee, SH | 1 |
Choi, SH | 1 |
Valenti, R | 1 |
Cantini, G | 1 |
Marcucci, R | 1 |
Marrani, M | 1 |
Migliorini, A | 1 |
Carrabba, N | 1 |
Comito, V | 1 |
Vergara, R | 1 |
Cerisano, G | 1 |
Parodi, G | 1 |
Abbate, R | 1 |
Gori, AM | 1 |
Gensini, GF | 1 |
Antoniucci, D | 1 |
Shaukat, A | 1 |
Al-Bustami, M | 1 |
Ong, PJ | 1 |
Jang, SW | 1 |
Kim, DB | 1 |
Kwon, BJ | 1 |
Shin, D | 1 |
Her, SH | 1 |
Park, CS | 1 |
Park, HJ | 1 |
Park, MW | 1 |
Cho, EJ | 1 |
Rho, TH | 1 |
Kim, JH | 1 |
Dixon, SR | 1 |
Grines, CL | 1 |
O'Neill, WW | 1 |
Barison, A | 1 |
de Carlo, M | 1 |
Bellini, F | 1 |
Capozza, PF | 1 |
Lunardini, A | 1 |
Petronio, AS | 1 |
Martín-Yuste, V | 1 |
Alvarez-Contreras, L | 1 |
Cola, C | 1 |
Brugaletta, S | 1 |
García Picart, J | 1 |
Martí, V | 1 |
Masotti, M | 1 |
Sabaté, M | 1 |
Yan, BP | 1 |
Ajani, AE | 1 |
Clark, DJ | 1 |
Duffy, SJ | 1 |
Andrianopoulos, N | 1 |
Brennan, AL | 1 |
Loane, P | 1 |
Reid, CM | 1 |
Hondo, T | 1 |
Matsumura, H | 1 |
Matsuda, K | 1 |
Iwamoto, A | 1 |
Eno, S | 1 |
Kimura, M | 1 |
Mannacio, VA | 1 |
Di Tommaso, L | 1 |
Antignan, A | 1 |
De Amicis, V | 1 |
Vosa, C | 1 |
Elefteriades, JA | 1 |
Meier, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00305162] | Phase 3 | 8,882 participants (Actual) | Interventional | 2006-04-30 | Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor) | ||
A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00385138] | Phase 3 | 5,364 participants (Actual) | Interventional | 2006-09-30 | Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor) | ||
A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand[NCT01301625] | 78 participants (Actual) | Observational | 2011-11-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Treatment Arm | 257 |
Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) | |||
---|---|---|---|---|
Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
(a patient could have multiple procedural events) (NCT00305162)
Timeframe: during index PCI
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 127 |
Clopidogrel Arm | 141 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 151 |
Clopidogrel Arm | 120 |
excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm (NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 78 |
Clopidogrel Arm | 65 |
(excluding STEMI) (NCT00305162)
Timeframe: randomization through 1 year after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 116 |
Clopidogrel Arm | 120 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 34 |
Clopidogrel Arm | 29 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 285 |
Clopidogrel Arm | 261 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 321 |
Clopidogrel Arm | 298 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 343 |
Clopidogrel Arm | 327 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 290 |
Clopidogrel Arm | 276 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 10 |
Clopidogrel Arm | 11 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 44 |
Clopidogrel Arm | 52 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 297 |
Clopidogrel Arm | 276 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 5 |
Clopidogrel Arm | 7 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 19 |
Clopidogrel Arm | 14 |
(NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 8 |
Clopidogrel Arm | 5 |
(NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Arm | 13 |
Clopidogrel Arm | 23 |
"Stroke is defined as a sudden, focal neurological defect resulting from a cerebrovascular cause that is not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or trauma. All suspected strokes were reviewed and adjudicated by the Clinical Events Committee (CEC) who considered all clinically relevant information and imaging studies to classify all strokes as:~primary hemorrhagic - stroke with focal collections of intracranial blood~ischemic cerebral infarction - stroke without focal collections of intracranial blood~infarction with hemorrhagic conversion - cerebral infarction with blood thought to represent hemorrhagic conversion and not primary bleeding~uncertain - no imaging or autopsy data are available." (NCT00305162)
Timeframe: randomization through 48 hours after randomization
Intervention | participants (Number) | |||
---|---|---|---|---|
primary hemorrhagic | infarction with hemorrhagic conversion | cerebral infarction | uncertain type | |
Cangrelor Arm | 1 | 0 | 5 | 0 |
Clopidogrel Arm | 0 | 0 | 7 | 0 |
Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 145 |
Clopidogrel | 91 |
Major bleeding (non-CABG-related) - Safety population excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm. (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 43 |
Clopidogrel | 29 |
mITT population (NCT00385138)
Timeframe: randomization through 1 year post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 94 |
Clopidogrel | 113 |
mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 35 |
Clopidogrel | 45 |
mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 6 |
Clopidogrel | 18 |
mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 213 |
Clopidogrel | 233 |
mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 180 |
Clopidogrel | 204 |
mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 227 |
Clopidogrel | 249 |
mITT population; (composite incidence) (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 185 |
Clopidogrel | 210 |
Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 9 |
Clopidogrel | 6 |
mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 37 |
Clopidogrel | 46 |
mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 19 |
Clopidogrel | 24 |
mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 189 |
Clopidogrel | 201 |
mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 177 |
Clopidogrel | 191 |
mITT population A patient could have multiple procedural events. (NCT00385138)
Timeframe: During index PCI
Intervention | participants (Number) |
---|---|
Cangrelor | 122 |
Clopidogrel | 142 |
mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 15 |
Clopidogrel | 28 |
mITT population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 5 |
Clopidogrel | 16 |
mITT (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 7 |
Clopidogrel | 5 |
mITT population (NCT00385138)
Timeframe: randomization through 30 days post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 6 |
Clopidogrel | 5 |
Major bleeding (non-CABG-related) - Safety population (NCT00385138)
Timeframe: randomization through 48 hours post randomization
Intervention | participants (Number) |
---|---|
Cangrelor | 4 |
Clopidogrel | 9 |
This is one of the Device and Procedure-Related Endpoints. Device Time is defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter. Device Time is shorter in duration than Procedure Time because it does not include the time required to perform transseptal access into the left atrium. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Minutes (Mean) |
---|---|
MitraClip Implant | 91.2 |
This is one of the Device and Procedure-Related Endpoints. Mean fluoroscopy duration during the MitraClip procedure. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Minutes (Mean) |
---|---|
MitraClip Implant | 41.2 |
Defined as successful MitraClip implantation with resulting MR of 2+ or less. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Participants (Count of Participants) |
---|---|
MitraClip Implant | 39 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 8.3 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 0.0 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 6.1 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: Baseline
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 0.0 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded. B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 91.5 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 12 months
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 85.3 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 30 days
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 96.1 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: Baseline
Intervention | percentage of participants (Number) |
---|---|
MitraClip Implant | 100 |
This is the Economic data reported to support the MitraClip System economic analysis. It is defined as the mean duration of time that patients spent in hospital following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days
Intervention | Days (Mean) |
---|---|
MitraClip Implant | 3.4 |
ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days
Intervention | Hours (Mean) |
---|---|
MitraClip Implant | 62.1 |
This is one of the Device and Procedure-Related Endpoints. Procedure Time is defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Minutes (Mean) |
---|---|
MitraClip Implant | 133.5 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 12 months
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 329.9 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 30 days
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 297.3 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 6 months
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 324.3 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: Baseline
Intervention | Meters (Mean) |
---|---|
MitraClip Implant | 271.0 |
This is one of the Device and Procedure-Related Endpoints. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
Intervention | Milliliters (Mean) |
---|---|
MitraClip Implant | 10.6 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 12 months
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline | 12 months | Difference (12 months - Baseline) | |
MitraClip Implant | 51.1 | 30.2 | -20.9 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 30 days
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline | 30 days | Difference (30 days - Baseline) | |
MitraClip Implant | 50.4 | 26.4 | -24.0 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 6 months
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline | 6 months | Difference (6 months - Baseline) | |
MitraClip Implant | 49.5 | 28.0 | -21.5 |
(NCT01301625)
Timeframe: 30 days
Intervention | Days (Mean) | |||
---|---|---|---|---|
All re-hospitalizations | Heart Failure-related re-hospitalizations | Other cardiac-related re-hospitalizations | Other non-cardiac-related re-hospitalizations | |
MitraClip Implant | 8.4 | 18.38 | 2.87 | 7.44 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 148.5 | 132.4 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 140.4 | 138.8 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | ml (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 141.7 | 141.8 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 161.1 | 150.1 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 152.9 | 148.2 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | Milliliters (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 158.2 | 151.3 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 12 months
Intervention | percent (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 46.9 | 47.4 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | percent (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 48.4 | 46.5 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | percent (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 47.2 | 44.6 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 97.8 | 91.7 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 88.5 | 89.0 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | Milliliter (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 93.3 | 93.2 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | cm (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 6.0 | 5.7 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | cm (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 5.9 | 5.7 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | cm (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 5.9 | 5.7 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | cm (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 4.6 | 4.5 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | cm (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 4.5 | 4.5 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | cm (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 4.5 | 4.4 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | cm^2 (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 3.8 | 2.3 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | cm^2 (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 3.5 | 2.3 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | cm^2 (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 3.5 | 2.4 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | mmHg (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 2.3 | 3.4 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | mmHg (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 2.3 | 3.5 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | mmHg (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 2.3 | 3.7 |
This is the economic data reported to support the MitraClip System economic analysis. (NCT01301625)
Timeframe: < or = 12 days
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Home | Home with home health care | Skilled nursing facility | Nursing home | Death | Other | |
MitraClip Implant | 70 | 4 | 1 | 0 | 2 | 1 |
This is one of the Device and Procedure-Related Endpoints. Implant Rate is defined as the rate of successful delivery and deployment of MitraClip device implant(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter. (NCT01301625)
Timeframe: Day 0 (On the day of procedure)
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
0 Mitra Clip devices | 1 Mitra Clip devices | 2 Mitra Clip devices | 3 Mitra Clip devices | |
MitraClip Implant | 1 | 41 | 35 | 1 |
Mital Valve Surgery Post-MitraClip Procedure; Surgery Types includes Replacement and Repair. (NCT01301625)
Timeframe: 30 days of Post-MitraClip Procedure
Intervention | Participants (Count of Participants) | |
---|---|---|
Recurring mitral regurgitation | Device failure | |
MitraClip Implant | 1 | 1 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 12 months
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 2 | 15 | 15 | 7 | 3 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 30 days
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 1 | 26 | 25 | 12 | 5 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 6 months
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 0 | 20 | 24 | 12 | 4 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: At discharge (≤7 days of index procedure)
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 1 | 38 | 22 | 9 | 3 | 1 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: Baseline
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
MitraClip Implant | 0 | 0 | 0 | 22 | 55 | 0 |
Second MitraClip device interventions are reported by Abbott Vascular personnel on Procedural Observation Forms. A second MitraClip device intervention is a good option for patients with MR following placement of the original MitraClip device. (NCT01301625)
Timeframe: Through 12 months
Intervention | Participants (Count of Participants) | |
---|---|---|
Recurring mitral regurgitation | Single leaflet device attachment (SLDA) | |
MitraClip Implant | 2 | 1 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 12 months
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 52.5 | 42.5 | 2.5 | 2.5 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 30 days
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 36.2 | 44.9 | 15.9 | 2.9 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 6 months
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 33.3 | 56.7 | 8.3 | 1.7 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: Baseline
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
NYHA I | NYHA II | NYHA III | NYHA IV | |
MitraClip Implant | 2.6 | 26.9 | 51.3 | 19.2 |
Defined as re-admission of patients to the hospital following discharge from the Clip procedure. (NCT01301625)
Timeframe: 30 days
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
All re-hospitalizations | Heart Failure-related re-hospitalizations | Other cardiac-related re-hospitalizations | Other non-cardiac-related re-hospitalizations | |
MitraClip Implant | 35 | 10 | 11 | 22 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | Percentage (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 44.6 | 36.8 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | Percentage (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 40.5 | 15.2 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | Percentage (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 38.9 | 25.8 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 12 Months
Intervention | ml (Mean) | |
---|---|---|
Baseline | 12 Months | |
MitraClip Implant | 49.8 | 73.3 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 30 Days
Intervention | ml (Mean) | |
---|---|---|
Baseline | 30 Days | |
MitraClip Implant | 61.9 | 25.6 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
Intervention | ml (Mean) | |
---|---|---|
Baseline | Discharge | |
MitraClip Implant | 55.5 | 25.1 |
2 reviews available for ticlopidine and Coronary Occlusion
Article | Year |
---|---|
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
Topics: Alleles; Asian People; Clopidogrel; Coronary Occlusion; Cytochrome P-450 CYP2C19; Databases, Factual | 2014 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp | 2010 |
2 trials available for ticlopidine and Coronary Occlusion
Article | Year |
---|---|
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Si | 2017 |
Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass, Off-Pum | 2012 |
10 other studies available for ticlopidine and Coronary Occlusion
Article | Year |
---|---|
Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
Topics: Aged; Clopidogrel; Coronary Occlusion; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Mid | 2020 |
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2015 |
Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus.
Topics: Aged; Blood Platelets; Chronic Disease; Clopidogrel; Coronary Occlusion; Diabetes Mellitus; Dose-Res | 2015 |
Chronic total occlusion--use of a 5 French guiding catheter in a 6 French guiding catheter.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Occlusion; Coronary Restenosis; Coronary | 2008 |
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occ | 2010 |
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug | 2011 |
[Usefulness of the Tornus® catheter in nondilatable coronary chronic total occlusion].
Topics: Aged; Cardiac Catheterization; Catheterization; Catheters; Clopidogrel; Coronary Angiography; Corona | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb | 2011 |
A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Aspirin; Autoantibodies | 2012 |
Clopidogrel and cardiac surgery: enemy or friend?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Occlusion; | 2012 |